Neurosearch fights charges of share price manipulation; Elan's Alzheimer's drug wins fast track;

@FierceBiotech: Popular: Is this the NIH Francis Collins wanted to create? Editor's corner | Follow @FierceBiotech

 @JohnCFierce: GSK China official: We inflated conference costs, handed out bribes, pocketed cash and upped drug prices. More | Follow @JohnCFierce

@RyanMFierce: Bioinformatics buy bolsters Life's diagnostics pact with Merck Serono. Report | Follow @RyanMFierce

 @EmilyMFierce: Animal studies produce many false positives. More | Follow @EmilyMFierce

> Denmark's Neurosearch says it is being prosecuted for share price manipulation related to statements it made regarding a Phase III study of Huntexil for Huntington's disease. The biotech is denying the charges and says it will work to resolve the issue. Story

> The FDA is assigning fast-track status to Elan's ($ELN) ELND005, which was submitted for the treatment of neuropsychiatric symptoms in Alzheimer's disease. Release 

> Chelsea Therapeutics says the FDA has accepted its resubmission of an NDA for Northera (droxidopa). Release

> Regulus is out to raise about $43 million from a new offering. Release

Pharma News

@FiercePharma: More tit-for-tat in Vivus proxy fight: FMC sues over meeting delay. $VVUS didn't like scoreboard, says Colin. Story | Follow @FiercePharma

 @EricPFierce: FDA says Cispharma didn't do enough to make sure blood tissue didn't get into drugs when worker injured. Article | Follow @EricPFierce

 @CarlyHFierce: NICE nixes Pfizer's CML drug Bosulif. Article | Follow @CarlyHFierce

> China crackdown: Is it designed to cut healthcare costs? More

> Novartis ex-chair Vasella nets new $5.2M exit package. Story

> Teva reveals CEO pay secret: Levin collected $4.1M in 2012. Article

Drug Delivery News

 @MichaelGFierce: Rexahn snags nanotech platform for cancer drug delivery. Article | Follow @MichaelGFierce

> CalTech team combines two breast cancer drugs using nanoparticles. Report

> Math models tailor drug delivery using patient DNA. Story

> Melbourne team concocts self-assembling, nanoengineered drug delivery tech. Article

> York students eye crowdfunding for nanoparticle cancer patch treatment work. Item

> Oramed raising $4.6M for oral insulin trial. News

Medical Device News

@FierceMedDev: Popular yesterday: For J&J, no device growth without Synthes. Article | Follow @FierceMedDev

 @MarkHFierce: The device tax has already cost the industry $1 billion. Editor's corner | Follow @MarkHFierce

@DamianFierce: Will all that M&A help Abbott turn its medical device sales around? More | Follow @DamianFierce

> St. Jude's Q2 produces mixed results, but CEO asserts progress. Story

> Abbott's device sales sag, but M&A could brighten the future. More

> Medical device ID plan faces delays. Item

And Finally… A new study says that cancer patients who have been treated with chemotherapy benefit from a significantly reduced risk of Alzheimer's. Story

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.